| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-2670 |
| P698 | PubMed publication ID | 17000686 |
| P50 | author | Kunle Odunsi | Q38296739 |
| Soldano Ferrone | Q90626068 | ||
| Alexia Iasonos | Q91946576 | ||
| Carol Aghajanian | Q91946596 | ||
| P2093 | author name string | William McGuire | |
| Shashikant Lele | |||
| David Spriggs | |||
| Martee Hensley | |||
| Silke Reinartz | |||
| Paul Sabbatini | |||
| Elizabeth Poynor | |||
| Jakob Dupont | |||
| Sally Schneider | |||
| Kerry Rodabaugh | |||
| Cathy Grande | |||
| James Kepner | |||
| Felicia Derosa | |||
| Phillip Livingston | |||
| Sybil Anderson | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | uterine tube | Q1233836 |
| P304 | page(s) | 5503-5510 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. | |
| P478 | volume | 12 |
| Q43793343 | Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study |
| Q37829443 | Abagovomab for ovarian cancer |
| Q35564007 | Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer |
| Q48104995 | Advances in ovarian cancer therapy |
| Q36832098 | Anti-idiotype antibodies in cancer treatment |
| Q28278814 | Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements |
| Q37351988 | Anti-idiotypic antibody abagovomab in advanced ovarian cancer |
| Q27000514 | Antibody-based immunotherapy for ovarian cancer: where are we at? |
| Q24193567 | Antigen-specific active immunotherapy for ovarian cancer |
| Q57688794 | Antigen-specific active immunotherapy for ovarian cancer |
| Q33859857 | CA125 in ovarian cancer |
| Q79790234 | CA125: megadaltons of novel opportunities |
| Q57903790 | Emerging drugs for ovarian cancer |
| Q35164189 | Immunotherapy for ovarian cancer. |
| Q36631249 | Immunotherapy in ovarian cancer |
| Q33713506 | MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress |
| Q57172159 | MUC16 as a novel target for cancer therapy |
| Q36230572 | Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach |
| Q38078400 | Monoclonal antibodies therapies for ovarian cancer |
| Q47221234 | New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness |
| Q36904860 | Novel agents in ovarian cancer. |
| Q47309343 | Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. |
| Q36739762 | Role of monoclonal antibodies in tumor-specific immunity |
| Q35088311 | Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies |
| Q38715211 | The Role of the Immune System in Ovarian Cancer and Implications on Therapy |
| Q21198791 | The detection, treatment, and biology of epithelial ovarian cancer |
| Q38117024 | Therapeutic vaccines for ovarian cancer |
| Q37909430 | Using monoclonal antibodies to stimulate antitumor cellular immunity |
| Q35029583 | Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. |
| Q37892583 | Vaccine-based clinical trials in ovarian cancer |
Search more.